Abstract
About this talk
Vildagliptin (VLG), recognized for its antidiabetic properties, offers a potential remedy for this prevalent condition due to its notable characteristics, including high solubility and a brief elimination half-life. This study aims to develop sustained-release VLG-encapsulated crosslinked chitosan-dextran sulfate nanoparticles (VLG-CDNs) through microreactor-assisted synthesis. Employing a design of experiment (DoE) approach systematically optimized the fabrication process. The optimized VLG-CDNs exhibited a reduced particle size of 217.4 ± 12.3 nm and an encapsulation efficiency of 76.3 ± 3.0. Scanning electron microscopy revealed smooth spherical surfaces of the VLG-CDNs. Subsequently, spray drying technology was utilized for dehydration, and reconstitution ability was assessed. The in vitro release profile demonstrated sustained VLG release over 12 hours. In-vitro antidiabetic efficacy was evaluated through glucose uptake assays in the skeletal muscle L6 cell line, along with assessments of α-amylase and α-glucosidase enzyme activities. The results indicate that the optimized VLG-CDNs present a promising nanoformulation for effectively managing diabetes mellitus.
Audience Take Away:
- Nanoparticle synthesis using Microreactor
- Characterization of Nanoparticles
- Evaluation of Nanoparticles
Speaker
About the speaker
